External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

HealthCare Global Enterprises / Equity Bottom-Up

<ul><li>HCG reported strong Q4FY25 results, with revenue growth of 18.3%, driven by a 3.5% YoY increase in ARPOB and ~16.7% growth in occupied days.</li><li>ARPOB stood at Rs 44,236, up 3.5% YoY, reflecting healthy growth. Occupancy improved to 67%, marking a 310 bps YoY increase.</li><li>The company reported EBITDA margins of 18.1%, down 50 bps YoY but increased by 220 bps QoQ. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

HCG reported strong Q4FY25 results, with revenue growth of 18.3%, driven by a 3.5% YoY increase in ARPOB and ~16.7% growth in occupied days.ARPOB stood at Rs 44,236, up 3.5% YoY, reflecting healthy growth. Occupancy improved to 67%, marking a 310 bps YoY increase.The company reported EBITDA margins of 18.1%, down 50 bps YoY but increased by 220 bps QoQ. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pick of the Week: Healthcare Global Enterprises Ltd - 28th June, 2025